Navigation Links
Scientists develop first ever drug to treat 'Celtic gene' in cystic fibrosis sufferers
Date:6/20/2011

An international research team led by Queen's University have developed a ground breaking treatment for Cystic Fibrosis sufferers. The new drug will benefit sufferers who have the 'Celtic Gene', a genetic mutation which is particularly common in Ireland.

The study, which was carried out by scientists at Queen's University Belfast, the University of Ulster, the Belfast Health and Social Care Trust and teams of researchers in Europe, USA and Australia found significant improvement in lung function, quality of life and a reduction in disease flare ups for those receiving the new treatment.

The drug (VX-770) is a significant breakthrough not only for those with the 'Celtic Gene', known as G551D, but also for all other Cystic Fibrosis sufferers as it indicates that the basic defect in Cystic Fibrosis can be treated. This is the first drug aimed at the basic defect in Cystic Fibrosis to show an effect. It is still too early to determine whether this treatment will improve life expectancy but the improvements in the breathing tests and the reduction in flare-ups would suggest survival will be better.

Stuart Elborn, Centre Director in the Centre for Infection and Immunity at Queen's University and co-leader of the study said: "The development of this drug is significant because it is the first to show that treating the underlying cause of Cystic Fibrosis may have profound effects on the disease, even among people who have been living with it for decades. The remarkable reductions in sweat chloride observed in this study support the idea that VX-770 improves protein function thereby addressing the fundamental defect that leads to CF."

Dr Judy Bradley, from the University of Ulster said: "This drug opens the defective channel in the lung cells of people with Cystic Fibrosis and allows proper lung clearance of bacteria. This is a ground breaking treatment because it treats the basic defect caused by the gene mutation in patients. Correcting the cells with this mutation shows that treatments aimed at the basic mutation can work leading to improvements in lung function and symptoms."

Dr Damien Downey, from the Belfast Health and Social Care Trust said: "The success of this study illustrates the benefits that come from collaborative work here in Northern Ireland. Not only will this breakthrough help patients in Ireland and the UK but it has the potential to change the lives for those with Cystic Fibrosis around the world. As a result of the recent work researchers from Queen's University, University of Ulster and clinicians from Belfast Health and Social Care Trust have been selected to join the European Cystic Fibrosis Society Clinical Trials Network. This means Cystic Fibrosis researchers in Northern Ireland will be collaborating with their European counterparts to work toward improved treatments for Cystic Fibrosis on a global level. "

The new drug will be submitted for licensing in the Autumn of this year and is expected to be available to patients by as early next year.


'/>"/>

Contact: Claire O'Callaghan
c.ocallaghan@qub.ac.uk
0044-028-909-75391
Queen's University Belfast
Source:Eurekalert

Related medicine news :

1. Scientists Turn Memory On, Off in Rats With Flip of Switch
2. Scientists Pinpoint Parts of Brain That Help People Recognize Themselves
3. Several methods for early diagnosis of Alzheimers disease developed by European scientists
4. Scientists image beginning stages of ovarian cancer growth with time-lapse technique
5. Scientists identify key component in lethal lung cancer complication
6. Swine flu spread was much wider than first thought, scientists say
7. Einstein scientists find crucial molecule involved in spread of breast cancer
8. Scientists create humanized mouse model for hepatitis C
9. Scientists unlock potential of frog skin to treat cancer
10. The New York Stem Cell Foundation awards fellowships to 7 innovative stem cell scientists
11. UCSB scientists discover new direction in Alzheimers research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... actively feeding the Frederick area economy by obtaining investment capital for emerging technology ... past 2½ years that have already resulted in more than a million dollars ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
Breaking Medicine Technology: